Medifast, Inc.

MED

US58470H1014

Food Processing

Market Closed - Nyse Other stock markets 04:00:02 2024-05-21 pm EDT			5-day change	1st Jan Change
24.39 ^USD	-0.16%		-7.75%	-63.72%

Apr. 30	Medifast Shares Drop as Q1 Adjusted Earnings, Revenue Decline; Sets Q2 Guidance	MT
Apr. 30	Wall Street Poised for Cautious Day Ahead of Key Numbers, Earnings, Fed Report	MT

Medifast, Inc. Provides Earnings Guidance for the Full-Year 2022

February 23, 2022 at 04:05 pm EST

Medifast, Inc. provided earnings guidance for the full-year 2022. The company expects full-year 2022 revenue to be in the range of $1.72 billion to $1.79 billion and full-year 2022 diluted EPS to be in the range of $14.50 to $16.00.

Latest news about Medifast, Inc.

Medifast Shares Drop as Q1 Adjusted Earnings, Revenue Decline; Sets Q2 Guidance	Apr. 30	MT
Wall Street Poised for Cautious Day Ahead of Key Numbers, Earnings, Fed Report	Apr. 30	MT
Top Premarket Decliners	Apr. 30	MT
North American Morning Briefing : More Earnings Roll In; Fed Decision Looms	Apr. 30	DJ
Transcript : Medifast, Inc., Q1 2024 Earnings Call, Apr 29, 2024	Apr. 29
Earnings Flash (MED) MEDIFAST Reports Q1 EPS $0.66	Apr. 29	MT
Earnings Flash (MED) MEDIFAST Reports Q1 Revenue $174.7M, vs. Street Est of $173.5M	Apr. 29	MT
Medifast, Inc. Provides Earnings Guidance for the Second Quarter of 2024	Apr. 29	CI
Medifast, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 29	CI
Medifast, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 20	CI
Transcript : Medifast, Inc., Q4 2023 Earnings Call, Feb 20, 2024	Feb. 20
Earnings Flash (MED) MEDIFAST Posts Q4 EPS $1.09, vs. Street Est of $0.96	Feb. 20	MT
Earnings Flash (MED) MEDIFAST Reports Q4 Revenue $191M, vs. Street Est of $184.2M	Feb. 20	MT
Medifast Provides Earnings Guidance for the First Quarter of 2024	Feb. 20	CI
Medifast, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 20	CI
Health Care Climbs After Fed Policy Move -- Health Care Roundup	Dec. 13	DJ
Medifast, LifeMD Collaborate to Offer Weight Management Solution; Medifast Scraps Quarterly Dividend	Dec. 13	MT
Transcript : LifeMD, Inc., Medifast, Inc. - Special Call	Dec. 13
Medifast's Board of Directors Elect to Discontinue the Company's Quarterly Cash Dividend	Dec. 13	CI
Medifast Initiates Business Transformation by Entering the Medically Supported Weight Loss Market through Collaboration with LifeMD, Inc	Dec. 13	CI
Tranche Update on Medifast, Inc.'s Equity Buyback Plan announced on December 9, 2013.	Nov. 06	CI
Medifast, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 06	CI
Transcript : Medifast, Inc., Q3 2023 Earnings Call, Nov 06, 2023	Nov. 06
Earnings Flash (MED) MEDIFAST Posts Q3 Revenue $235.9M, vs. Street Est of $232.1M	Nov. 06	MT
Medifast, Inc. Provides Earnings Guidance for the Full Year 2023	Nov. 06	CI

Chart Medifast, Inc.

Duration

Period

More charts

Company Profile

Medifast, Inc. is a health and wellness company. The Company provides a habit-based and coach-guided lifestyle solution OPTAVIA, which provides people with a comprehensive approach to help them achieve lasting optimal health and wellbeing. OPTAVIA's lifestyle plans deliver clinically proven health benefits as well as evidence-based tools, including scientifically developed products and a framework for habit creation reinforced by independent coaches and community support. Through a collaboration with the virtual primary care provider LifeMD, Inc (LifeMD), OPTAVIA customers have access to board-certified affiliated clinicians and medications, such as GLP-1s, that support treatment plans for obesity and other health conditions. OPTAVIA Coaches introduce customers to a set of healthy habits, and offer OPTAVIA-branded products, including Fuelings as well as OPTAVIA ACTIVE, a line of essential amino acid supplements and protein powders. Its operations are conducted through its subsidiaries.

Sector

Food Processing

Calendar

2024-06-19 - Annual General Meeting

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Medifast, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

24.39 USD

Average target price

25 USD

Spread / Average Target

+2.50%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Special Foods & Wellbeing Products

	1st Jan change	Capi.
MEDIFAST, INC.	-63.72%	261M
ZHEJIANG NHU COMPANY LTD.	+17.57%	8.47B
BELLRING BRANDS, INC.	+3.37%	7.6B
CSPC INNOVATION PHARMACEUTICAL CO., LTD.	+5.65%	6.26B
THE SIMPLY GOOD FOODS COMPANY	-4.57%	3.78B
XIAMEN KINGDOMWAY GROUP COMPANY	-2.14%	1.35B
HERBALIFE LTD.	-26.41%	1.12B
SIRIO PHARMA CO., LTD.	+15.61%	998M
USANA HEALTH SCIENCES, INC.	-7.15%	948M
JAMIESON WELLNESS INC.	-16.17%	808M

Special Foods & Wellbeing Products

Medifast, Inc.

Equities

MED

US58470H1014

Food Processing

Medifast, Inc. Provides Earnings Guidance for the Full-Year 2022

EPS Revisions